chevron_leftBack
As of 24 April 2025, Nymox Pharmaceutical Corp. has a market cap of $11.14M USD, ranking #32650 globally and #3 in Bahamas. It ranks #3269 in the Healthcare sector, and #1086 in the Biotechnology industry.
Key Stats
Market Cap
$11.14MUSD
Enterprise Value
$13.7MUSD
EBITDA (TTM)
-$8.34MUSD
Net Income (TTM)
-$8.95MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Paul Averback
open_in_new
Employees
16
Founded
1989
Website
nymox.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 7.1% | 30% | -5.7% | -21% | -61% |
Upcoming Earnings
Earnings Date
Fri, May 2
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NYMXF
Nymox Pharmaceutical Corp
ISIN: BSP733981026
Shares Out.:
Shares Outstanding:
93.54M1
Shares Float:
51.83M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.1178 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Nymox Pharmaceutical Corp.
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for detecting smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. The company was founded in 1989 and is headquartered in Nassau, Bahamas.
